dc.creatorBottecchia, Marcelle
dc.creatorSouto, Francisco J. D.
dc.creatorO, Kycia M. R.
dc.creatorAmendola, Marcia
dc.creatorBrandão, Carlos E.
dc.creatorNiel, Christian
dc.creatorGomes, Selma A.
dc.date2018-08-02T14:57:58Z
dc.date2018-08-02T14:57:58Z
dc.date2008
dc.date.accessioned2023-09-26T20:07:30Z
dc.date.available2023-09-26T20:07:30Z
dc.identifierBOTTECCHIA, Marcelle; et al. Hepatitis B virus genotypes and resistance mutations in patients under long term lamivudine therapy: characterization of genotype G in Brazil. BMC Microbiology, v. 8, n.11, 10p, Jan. 2008.
dc.identifier1471-2180
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/27796
dc.identifier10.1186/1471-2180-8-11
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8849086
dc.descriptionLamivudine is an oral nucleoside analogue widely used for the treatment of chronic hepatitis B. The main limitation of lamivudine use is the selection of resistant mutations that increases with time of utilization. Hepatitis B virus (HBV) isolates have been classified into eight genotypes (A to H) with distinct geographical distributions. HBV genotypes may also influence pathogenic properties and therapeutic features. Here, we analyzed the HBV genotype distribution and the nature and frequency of lamivudine resistant mutations among 36 patients submitted to lamivudine treatment for 12 to 84 months.
dc.formatapplication/pdf
dc.languageeng
dc.publisherBioMed Central
dc.rightsopen access
dc.subjectGenótipos do vírus da Hepatite B
dc.subjectMutações
dc.subjectResistência a medicamentos
dc.subjectTerapia com Lamivudina
dc.subjectBrasil
dc.subjectHepatitis B virus genotypes
dc.subjectresistance mutations
dc.subjectlamivudine therapy
dc.subjectBrazil
dc.titleHepatitis B virus genotypes and resistance mutations in patients under long term lamivudine therapy: characterization of genotype G in Brazil
dc.typeArticle


Este ítem pertenece a la siguiente institución